The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Is NVO Stock Falling Pre-Market Today?